This success story showcases how the analytics center of excellence delivery model improved the relevance and quality of scientific content for a global pharma intelligence provider.

As we know...

Pharma companies rely on high-quality, timely and actionable intelligence to drive strategic decision-making and unlock value at speed. Data-led insights are vital to core enterprise objectives, including navigating market complexities, adapting to evolving customer expectations and optimizing portfolio strategy.

This puts the onus on intelligence and research firms to provide pharma companies with calibrated and connected data to support the end goal of helping patients get access to life-saving therapies.

The challenge for the pharma research firm was...

Meeting its clients’ growing demand for comprehensive coverage, high-quality analysis and rapid turnaround. The firm lacked the specialized skills required to process complex and unstructured scientific information, derive insights and provide an up-to-date view of the global drug pipeline and sales forecasts.

Compounding the challenge was the pressure to scale operations as the clients’ needs grew with geographic and portfolio expansions. With a lean team possessing generic skills, the firm found it difficult to manage existing content, let alone add new datasets or increase coverage.

WNS stepped in as a research and analytics partner...

Leveraging Triange Center of Excellence (CoE), a key pillar of WNS Triange (our data, analytics and AI practice). We implemented a data management and analysis solution that involved deploying highly specialized domain experts, leveraging best practices in operations delivery, and incorporating Artificial Intelligence (AI) tools specific to the pharma and life sciences sector.

Key aspects of the solution included:

  • Employing highly sophisticated tools to acquire unstructured scientific information from public sources, third-party sources, syndicated reports and clinical trial registries of multiple countries
  • Deploying domain experts to identify and monitor drug-specific competitive information, resulting in the creation of therapy records
  • Integrating equity research into therapy records to publish a global view of the healthcare market
  • Developing an authoring tool to record, publish and report this highly strategic content from across the depth and breadth of global coverage

Streamlined operations enabled the pharma research firm to…

Retain and grow its customer base while expanding its global coverage of insights across the pharma, biotech and MedTech sectors. By steering end-to-end content operations, WNS created transformative value for the client through the constant enrichment and addition of datasets and ideation on new revenue streams. Furthermore, transitioning content operations enabled the firm to focus on new product development.

Tangible benefits for the client included:

  • 100x increase in company coverage
  • 50x scale-up in database coverage and geographic expansion
  • Less than 24-hour turnaround time on key projects

About WNS Triange:

WNS Triange (formerly WNS Research and Analytics practice) powers business growth and innovation for 120+ global companies with data, analytics and Artificial Intelligence (AI). Driven by a specialized team of over 4000 analysts, data scientists and domain experts, WNS Triange helps translate data into actionable insights for impactful decision-making. Built on the pillars of consulting (Triange Consult), future-ready platforms (Triange Nxt), and domain and technology (Triange CoE), WNS Triange seamlessly blends strategy, industry-specific nuances, AI and Machine Learning (ML) operations, and intelligent cloud platforms.

Driving a futuristic edge are WNS Triange’s modular cloud-based platforms and solutions leveraging advanced AI and ML to provide end-to-end integration and processing of data to actionable insights. WNS Triange leverages the combined strength of WNS’ domain expertise, co-creation labs, strategic partnerships and outcome-based engagement models.

Join the conversation